Background {#Sec1}
==========

The hip is the third joint most commonly affected by osteoarthritis (OA) \[[@CR1]\]. No therapeutic cure exists for hip OA. Therefore, predicting which patients with hip OA are more likely to progress in their disease is of special interest, particularly if these predictive factors are potentially modifiable.

In 2002, Lievense et al. published a systematic review in which they identified several predictive factors for the progression of hip OA \[[@CR2]\]. They used a best-evidence synthesis to draw conclusions about the available evidence per factor. Strong evidence was found for more rapid progression in patients with a superior or superolateral migration of the femoral head or an atrophic bone response. Conversely, strong evidence was found for no association between progression of hip OA and obesity. In 2009, Wright et al. also reviewed the known prognostic factors and their quality of evidence \[[@CR3]\]. They concluded that only a few factors are strongly associated with the progression of hip OA, i.e., age, joint space width, migration of the femoral head, femoral osteophytes, bony sclerosis, Kellgren and Lawrence (K-L) grade 3, hip pain at baseline, and a Lequesne index score \> 10. In that review, acetabular osteophytes showed no association with progression. Furthermore, de Rooij et al. studied the factors predicting the course of pain and function. They found strong evidence that higher comorbidity count and lower vitality predict a worsening of physical function \[[@CR4]\]. Although all reviews described additional predictive factors, the evidence for these factors was either limited or conflicting.

Since the literature search of Wright et al. (in October 2008) and de Rooij et al. (in July 2015) more research on prognostic factors of hip OA have been conducted, and new methods to assess and review prognostic studies have been developed \[[@CR5]\].

Therefore, the aim of this present study was to systematically review the evidence of patient, health, and diagnostic variables associated with the progression of hip OA.

Methods {#Sec2}
=======

Search of the literature {#Sec3}
------------------------

A search was made in the databases of Embase, MEDLINE (OvidSP), Web-of-Science, Cochrane Library, PubMed publisher, and Google Scholar from the inception of the database until 14 March 2019, using the keywords *hip*, *osteoarthritis*, and *prognosis* (and their synonyms). We excluded congress abstracts and editorial letters from our search by setting these as limits to restrain the number of found citations without losing valuable citations. The reference lists of relevant articles were screened for additional relevant studies. A complete syntax of the search can be found in Additional file [1](#MOESM1){ref-type="media"}. The process of the search was assisted and partly conducted by an experienced medical librarian.

Criteria for selection of studies {#Sec4}
---------------------------------

The following are the criteria for the selection of studies: The study should investigate the factors associated with the progression of hip OA.The article was written in English, Dutch, German, French, Spanish, Italian, Danish, Norwegian, or Swedish. These languages were sufficiently mastered by at least two reviewers.The article was available in full text.Patients in the study reported complaints like pain, disability, or stiffness of the hip, suspected or confirmed (radiographic or clinical criteria) to originate from OA of the hip.The study design was a cohort or a case-control study or a randomized controlled trial in which the estimation of the prognostic factor was adjusted for the intervention or only investigated in the control group.Progression was determined radiographically or clinically. Radiographic progression could be determined by, for example, X-ray or MRI. Examples of clinical progression were worsening of pain or function or reaching the point of indication for total hip replacement (THR).Follow-up should be at least 1 year (based on the recommendations for measuring structural progression \[[@CR6]\]).The study was excluded if the population under investigation had a specific underlying pathology, such as trauma (fractures), infection, rheumatoid arthritis, ankylosing spondylitis, Perthes' disease, tuberculosis, hemochromatosis, sickle cell disease, Cushing's syndrome, and femoral head necrosis.

Selection of studies {#Sec5}
--------------------

CHT screened all the titles and abstracts and excluded articles that did not investigate patients with OA of the hip. Secondly, CHT and PAJL independently selected the titles and abstracts using the selection criteria to decide which articles required the retrieval of full text; in case of disagreement, the full text was retrieved. Then, all full texts were independently assessed by CHT and PAJL to include all relevant studies according to the selection criteria. In case of disagreement and both reviewers were unable to reach consensus, SMABZ made the final decision.

Data extraction {#Sec6}
---------------

Information on the design, setting, study population (e.g., recruitment period, age, gender, definition of hip OA), number of participants, follow-up period, loss to follow-up, prognostic factors, assessment of progression, outcomes, and strength of association were extracted using standardized forms by CHT and checked by PAJL.

Prognostic factors were divided into patient variables, disease characteristics, and chemical or imaging markers. Outcomes were divided into clinical progression, radiographic progression, or (indication for) receiving a THR.

If outcomes were measured at several follow-up moments, all moments were extracted. After the collection of all data, the follow-up moments that were in the closest range to each other were used for the evidence synthesis.

Risk of bias assessment {#Sec7}
-----------------------

The quality of all included cohort studies was evaluated using the QUIPS tool \[[@CR5], [@CR7]\]. Studies were assessed on six domains: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting. An overview of all domains and their items is presented in Additional file [2](#MOESM2){ref-type="media"}. Each study was independently scored by CHT and by a second reviewer (DMJD, SMABZ, PKB, JBMRO, or PAJL). In case of disagreement, they attempted to reach consensus; if this failed, a third reviewer (JBMRO or PAJL) made the final decision.

Evidence synthesis {#Sec8}
------------------

A meta-analysis was considered if clinical heterogeneity was low, with respect to the study population, the risk of bias, and the definition of prognostic factors and defined hip OA progression. In case of a meta-analysis, an adjusted GRADE assessment for prognostic research was used to determine the strength of the evidence \[[@CR8]\].

If the level of heterogeneity of the studies was high, we refrained from pooling in the main analysis and performed a qualitative evidence synthesis. Associations were categorized as positive, negative, or no association. Ranking of the levels of evidence was based on Lievense et al. \[[@CR2]\] and Davis et al. \[[@CR9]\]: Strong evidence: consistent findings (≥ 75% of the studies showing the same direction of the association) in two or more studies with a low risk of bias in all domains of the QUIPS toolModerate evidence: consistent findings in more than two studies with a moderate or high risk of bias in one or more domains of the QUIPS tool or consistent findings in two studies, of which one study has a low risk of bias in all domains of the QUIPS toolLimited evidence: one study with a low risk of bias in all domains of the QUIPS tool or two studies with a moderate or high risk of bias in one or more domains of the QUIPS toolConflicting evidence: \< 75% of the studies showing the same direction of the association

If a prognostic factor was described in two different articles that investigated the same study cohort and outcome of progression, one study was selected to include in the evidence synthesis. In this case, we selected the article according to a decision tree: (1) lowest risk of bias, (2) prognostic factor is the primary outcome of the study, and (3) the largest number of participants.

Post hoc changes to the study protocol {#Sec9}
--------------------------------------

After contact with one of the developers of the QUIPS tool, we learned that it is not validated to judge the risk of bias of case-control studies and would probably not adequately take into account the higher risk of recall bias and the selection bias of case-control studies. Therefore, we decided to exclude case-control studies from our evidence synthesis, except for nested case-control studies. Nested case-control studies are less prone to selection and recall bias because of the underlying known cohort \[[@CR10]\], which can be judged using the QUIPS tool.

Results {#Sec10}
=======

Included studies {#Sec11}
----------------

The initial search yielded 6429 citations of which 57 articles were finally included. Figure [1](#Fig1){ref-type="fig"} shows the reasons for the study exclusion, and Table [1](#Tab1){ref-type="table"} presents a brief overview of the characteristics of the 57 included studies (a more extensive overview is available in Additional file [3](#MOESM3){ref-type="media"}). Of the 57 studies, 48 were cohort studies (37 with a prospective design), 4 were nested case-control studies, and 5 were case-control studies. These last 5 studies were excluded from the evidence synthesis for the reasons mentioned above. Fig. 1Flowchart of the search and selection of studies Table 1Characteristics of the selected studiesStudyDesignParticipants in the cohort (*n*)Assessment of progressionFollow-up periodAgricola et al. \[[@CR11]\]Prospective cohort (CHECK)1002 (analyzed 723 patients)THR5 yearsAgricola et al. \[[@CR12]\]Prospective cohort (CHECK)1002 (analyzed 550 women)THR due to OA5 yearsAgricola et al. \[[@CR12]\]Nested case-control (Chingford cohort)1003 (analyzed 114)THR due to OA19 yearsAuquier et al. \[[@CR13]\]Retrospective cohort131Increase in stage of pain and function, stages minimal, moderate, moderate-severe, severe6--23 yearsBarr et al. \[[@CR14]\]Case-control195 (analyzed 102 patients)THR (compared to non-progression hips: increase of ≤ 1 K-L grade)5 yearsBastick et al. \[[@CR15]\]Prospective cohort (CHECK)545 (analyzed 363 patients)NRS score for pain, group moderate progression compared to mild pain. Groups based on LCGA5 yearsBastick et al. \[[@CR16]\]Prospective cohort (CHECK)588 (analyzed 538)THR5 yearsBergink et al. \[[@CR17]\]Prospective cohort (Rotterdam I)1761. Increase ≥ 1 K-L grade2. Decrease ≥ 1 mm of joint spaceAverage 8.4 yearsBirn et al. \[[@CR18]\]Case-control94 (5 cases, 89 controls)Rapidly destructive OA: \> 2 mm or \> 50% JSN/yearNRBirrell et al. \[[@CR19]\]Prospective cohort195Time to being put on a waiting list for THR36 monthsBouyer et al. \[[@CR20]\]Prospective cohort (KHOALA)242 (analyzed 133 patients)1. Increase ≥ 1 K-L grade2. Increase ≥ 1 JSN score3. Time to THR3 yearsCastano Betancourt et al. \[[@CR21]\]Prospective cohort (GOAL)189JSN ≥ 20% compared to baseline or THR2 yearsChaganti et al. \[[@CR22]\]Nested case-control (SOF)168 cases and 173 controlsDecrease in MJS of 0.5 mm, increase of ≥ 1 in summary grade, increase ≥ 2 in total osteophyte score, or THR for OAAverage 8.3 yearsChevalier et al. \[[@CR23]\]Prospective cohort30Rapid evolution: JSN \> 0.6 mm/year1 yearConrozier et al. \[[@CR24]\]Case-control104 (analyzed 10 cases, 23 controls)Rapidly progressive hip OA: severe hip pain, symptom onset within the last 2 years, annual rate of JSN \> 1 mm, ESR \< 20 mm/h, absence of detectable inflammatory or crystal-induced joint diseaseNRConrozier et al. \[[@CR25]\]Retrospective cohort89Radiographic: YMN, calculated from MJS in mm/year18--300 monthsConrozier et al. \[[@CR26]\]Prospective cohort48JSN in mm/year1 yearDanielsson \[[@CR27], [@CR28]\]Prospective cohort1681. Increase in pain index 0--52. Operation because of hip OA3. Increase in radiographic index 0--108--12 yearsvan Dijk et al. \[[@CR29]\]Prospective cohort1231. Decrease in WOMAC function2. Increase in seconds of timed walking test3 yearsvan Dijk et al. \[[@CR30]\]Prospective cohort1231. Decrease in WOMAC function2. Increase in seconds of timed walking test3 yearsDorleijn et al. \[[@CR31]\]Prospective cohort (GOAL)222 (analyzed 111 patients)VAS score for pain, group highly progressive compared to mild pain groups based on LCGA2 yearsDougados et al. \[[@CR32]\]Prospective cohort (ECHODIAH)508 (analyzed 461 patients)Radiological: ≥ 0.6 mm decrease in JSW1 yearDougados et al. \[[@CR33]\]Prospective cohort (ECHODIAH)508 (analyzed 463 patients)Radiological: \> 0.5 mm decrease in JSW2 yearsDougados et al. \[[@CR34]\]Prospective cohort508Time to the requirement of THR3 yearsFukushima et al. \[[@CR35]\]Prospective cohort20Increase in Tönnis grade25 monthsGolightly et al. \[[@CR36]\]Prospective cohort (Johnston County)1453Increase in K-L grade or increase in hip symptoms (mild, moderate, severe)3--13 yearsGossec et al. \[[@CR37]\]Prospective cohort741 (analyzed 505 patients)THR2 yearsHartofilakidis et al. \[[@CR38]\]Retrospective cohort210THR2 to \> 10 yearsHawker et al. \[[@CR39]\]Prospective cohort2128Time to THR6.1 yearsHoeven et al. \[[@CR40]\]Prospective cohort (Rotterdam I)5650 (number analyzed: NR)Increase ≥ 1 K-L grade baseline to follow-up10 yearsHolla et al. \[[@CR41]\]Prospective cohort (CHECK)588Moving into a higher group (quintiles of WOMAC-PF 0--68) or remaining within the three highest groups2 yearsJuhakoski et al. \[[@CR42]\]Prospective cohort1181. WOMAC pain (0--100)2. WOMAC function (0--100)2 yearsKalyoncu et al. \[[@CR43]\]Retrolective cohort (ECHODIAH)192THR10 yearsKelman et al. \[[@CR44]\]Nested case-control (SOF)396 (cases 197, controls 199)Decrease in minimum joint space of ≥ 0.5 mm, an increase of ≥ 1 in the summary grade, an increase of ≥ 2 in total osteophyte score, or THR8.3 yearsKerkhof et al. \[[@CR45]\]Prospective cohort (Rotterdam I)1610Radiologic: JSN ≤ 1.0 mm or THR during follow-upNRKopec et al. \[[@CR46]\]Prospective cohort (Johnston County)1590 (analyzed 571 people)Increase ≥ 1 in K-L grade3--13 yearsLane et al. \[[@CR47]\]Prospective cohort (SOF)745Decrease in minimum joint space of ≥ 0.5 mm, an increase of ≥ 1 in the summary grade, an increase of ≥ 2 in total osteophyte score, or THR8 yearsLane et al. \[[@CR48]\]Nested case-control (SOF)342Radiological: decrease in minimum joint space of ≥ 0.5 mm, an increase of ≥ 1 in the summary grade, an increase of ≥ 2 in total osteophyte score, or THR8.3 yearsLaslett et al. \[[@CR49]\]Prospective cohort (TasOAC)1099 (analyzed 765 people)WOMAC pain (0--100)2--4 yearsLedingham 1993 \[[@CR50]\]Prospective cohort1361. Global assessment of radiographic change2. THR3--73 monthsLievense et al. \[[@CR51]\]Prospective cohort224 (analyzed 163 patients)THR5.8 yearsMaillefert et al. \[[@CR52]\]Prospective cohort (ECHODIAH)5081. Decrease in JSW \> 50% during the first year follow-up2. THR in 1--5 years of follow-up5 yearsMazieres et al. \[[@CR53]\]Prospective cohort (ECHODIAH)507 (analyzed 333 patients)JSN ≥ 0.5 mm or THP3 yearsNelson et al. \[[@CR54]\]Prospective cohort (Johnston County)3091. Increase in K-L grade2. Increase in osteophyte severity grade3. Increase in JSN severity grade5 yearsPerry et al. \[[@CR55]\]Case-control44Radiographic: progressive deterioration5--14 yearsPeters et al. \[[@CR56]\]Prospective cohort587 (analyzed 214 patients)New Zealand score 0--80 (combination of pain and function)7 yearsPisters et al. \[[@CR57]\]Prospective cohort149Increase in WOMAC function on average over time (measured at 1, 2, 3, 5 years)5 yearsPollard 201et al. 2 \[[@CR58]\]Prospective cohort264Signs on examination of hip OA or symptoms at baseline and signs and symptoms at follow-up5 yearsReijman et al. \[[@CR59]\]Prospective cohort (Rotterdam I)1235JSN ≥ 1.0 mm in at least 1 of 3 compartments (lateral, superior, axial)6.6 yearsReijman et al. \[[@CR60]\]Prospective cohort (Rotterdam I)1904Radiologic: JSN ≤ 1.0 mm or THR during follow-up6.6 yearsReijman et al. \[[@CR61]\]Prospective cohort (Rotterdam I)16761. JSN of ≥ 1 mm2. JSN of ≥ 1.5 mm3. Increase of ≥ 1 K-L grade6.6 yearsSolignac \[[@CR62]\]Prospective cohort (ECHODIAH)507 (analyzed 333 patients)JSN ≥ 0.5 mm or THP3 yearsvan Spil et al. \[[@CR63]\]Prospective cohort (CHECK)1002 (analyzed 178 patients)Radiographic: ≥ 1 K-L grade increase5 yearsThompson et al. \[[@CR64]\]Case-control34 cases, controls: NRRapidly progressive OA: loss of bone or a combined loss of bone and articular cartilage at rate \> 5 mm per year18 monthsTron et al. \[[@CR65]\]Retrospective cohort39Mean annual JSN in mmNRVerkleij et al. \[[@CR66]\]Prospective cohort (GOAL)222 (analyzed 111 patients)VAS score for pain, group highly progressive compared to mild pain, groups based on LCGA2 yearsVinciguerra et al. \[[@CR67]\]Retrospective cohort149Time to THRVariable*NR* not reported, *OA* osteoarthritis *THR* total hip replacement, *K-L grade* Kellgren and Lawrence grade, *MJS* minimum joint space, *JSN* joint space narrowing, *JSW* joint space width, *YMN* yearly mean narrowing, *LCGA* latent class growth analysis, *ESR* erythrocyte sedimentation rate, *NRS* numeric rating scale, *VAS* visual analog scale

Risk of bias assessment {#Sec12}
-----------------------

In 68% of all assessed domains from all studies, there was an immediate consensus between the reviewers (Cohen's kappa 0.375, linear weighted kappa 0.484). In 9 assessments of a domain (3%) in 6 different studies, a third reviewer made the final judgment. In total, 15 studies scored a low risk of bias in all domains \[[@CR15], [@CR16], [@CR21], [@CR29], [@CR30], [@CR32], [@CR34], [@CR37], [@CR41], [@CR44], [@CR47], [@CR49], [@CR53], [@CR57], [@CR63]\] (Table [2](#Tab2){ref-type="table"}). Table 2Risk of bias assessment summary (QUIPS)StudyStudy participationStudy attritionPrognostic factor measurementOutcome measurementStudy confoundingStatistical analysis and reportingAgricola et al. \[[@CR11]\]LowLowModerateLowLowLowAgricola et al. \[[@CR12]\]LowLowModerateLowModerateLowAuquier et al. \[[@CR13]\]ModerateModerateLowModerateHighModerateBastick et al. \[[@CR15]\]*LowLowLowLowLowLow*Bastick et al. \[[@CR16]\]*LowLowLowLowLowLow*Bergink et al. \[[@CR17]\]LowModerateModerateLowLowModerateBouyer et al. \[[@CR20]\]LowHighModerateModerateLowLowBirrell et al. \[[@CR19]\]LowLowModerateLowLowLowCastano Betancourt et al. \[[@CR21]\]*LowLowLowLowLowLow*Chaganti et al. \[[@CR22]\]LowLowLowLowModerateLowChevalier et al. \[[@CR23]\]ModerateLowLowLowModerateModerateConrozier et al. \[[@CR25]\]ModerateLowLowLowLowLowConrozier et al. \[[@CR26]\]ModerateLowLowLowLowLowDanielsson \[[@CR27], [@CR28]\]LowHighHighHighHighHighvan Dijk et al. \[[@CR29]\]*LowLowLowLowLowLow*van Dijk et al. \[[@CR30]\]*LowLowLowLowLowLow*Dorleijn 2015 \[[@CR31]\]LowLowModerateLowModerateLowDougados et al. \[[@CR32]\]*LowLowLowLowLowLow*Dougados et al. \[[@CR33]\]LowLowLowModerateHighModerateDougados et al. \[[@CR34]\]*LowLowLowLowLowLow*Fukushima et al. \[[@CR35]\]ModerateLowLowHighHighLowGolightly et al. \[[@CR36]\]LowModerateLowLowLowLowGossec et al. \[[@CR37]\]*LowLowLowLowLowLow*Hartofilakidis et al. \[[@CR38]\]ModerateModerateModerateModerateHighHighHawker et al. \[[@CR39]\]ModerateLowLowLowLowLowHoeven et a. \[[@CR40]\]LowModerateLowLowLowLowHolla et al. \[[@CR41]\]*LowLowLowLowLowLow*Juhakoski et al. \[[@CR42]\]LowLowLowModerateLowLowKalyoncu et al. \[[@CR43]\]LowLowModerateModerateLowLowKelman et al. \[[@CR44]\]*LowLowLowLowLowLow*Kerkhof et al. \[[@CR45]\]LowModerateModerateLowLowLowKopec et al. \[[@CR46]\]LowModerateLowLowLowLowLane et al. \[[@CR47]\]*LowLowLowLowLowLow*Lane et al. \[[@CR48]\]ModerateLowModerateLowLowLowLaslett et al. \[[@CR49]\]*LowLowLowLowLowLow*Ledingham et al. \[[@CR50]\]ModerateModerateModerateHighHighHighLievense et al. \[[@CR51]\]LowLowModerateLowLowLowMaillefert et al. \[[@CR52]\]LowLowLowModerateModerateModerateMazieres et al. \[[@CR53]\]*LowLowLowLowLowLow*Nelson et al. \[[@CR54]\]LowModerateLowLowLowLowPeters et al. \[[@CR56]\]LowModerateModerateLowModerateLowPisters et al. \[[@CR57]\]*LowLowLowLowLowLow*Pollard et al. \[[@CR58]\]LowLowLowModerateLowLowReijman et al. \[[@CR59]\]LowModerateLowLowLowLowReijman et al. \[[@CR60]\]LowModerateLowLowLowLowReijman et al. \[[@CR61]\]LowModerateLowLowLowLowSolignac \[[@CR62]\]LowLowLowLowModerateLowvan Spil et al. \[[@CR63]\]*LowLowLowLowLowLow*Tron et al. \[[@CR65]\]HighHighHighModerateHighModerateVerkleij et al. \[[@CR66]\]LowLowLowLowModerateLowVinciguerra et al. \[[@CR67]\]LowModerateHighLowHighHighStudies with a low risk of bias in all domains are presented in italics

Prognostic factors {#Sec13}
------------------

We identified 154 possible prognostic factors: 23 patient variables, 77 disease characteristics, and 54 chemical markers or imaging markers. Fifty-one factors were only investigated once in a single cohort or study (not a low risk of bias study) and could not be included in the evidence synthesis. An overview of all the results and risk of bias assessment of the studies describing these factors is presented in Additional file [4](#MOESM4){ref-type="media"}. The remaining 103 factors were included in the evidence synthesis. To decrease heterogeneity, evidence synthesis was done separately per group of outcomes (radiological progression, clinical progression, or THR). However, heterogeneity was still considered high in each outcome group, mainly within respect to the definition of the prognostic factor, progression, and measure of the association. Therefore, we refrained from pooling and performed a best-evidence synthesis. If a factor could not be subdivided because it was described by two or three studies that used a definition of progression, all in a separate group of outcome, we combined the groups of outcomes. The results of these factors are presented in Additional file [5](#MOESM5){ref-type="media"}.

Evidence for factors predicting progression {#Sec14}
-------------------------------------------

Strong evidence was found for a higher K-L grade at baseline, superior or (supero) lateral femoral head migration, and subchondral sclerosis to be predictive of faster progression to THR or more patients progressing to THR. Body mass index was found not to be predictive of faster or more progression to THR (Table [3](#Tab3){ref-type="table"}). Table 3Factors predicting (indication for) total hip replacement (THR)Prognostic factorStudiesAssociationsBest-evidence synthesisPatient variables No association  Body mass indexStrong evidence for no association2 low risk of bias cohorts \[[@CR16], [@CR37]\]5 cohorts \[[@CR20], [@CR39], [@CR50], [@CR51], [@CR67]\]No, noNo, no, no, negative, positive  FemaleModerate evidence for no association3 low risk of bias cohorts \[[@CR16], [@CR34], [@CR37]\]5 cohorts \[[@CR20], [@CR39], [@CR50]--[@CR52]\]No, positive, noNo, no, no, no, no  Lower educational levelModerate evidence for no association1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR39]\]NoNo  Western or White ethnicityModerate evidence for no association1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR39]\]NoNo  Alcohol consumptionLimited evidence for no association1 low risk of bias cohort \[[@CR16]\]No Conflicting evidence  Higher age at baselineConflicting evidence3 low risk of bias cohorts \[[@CR16], [@CR34], [@CR37]\]5 cohorts \[[@CR20], [@CR39], [@CR50], [@CR51], [@CR67]\]No, positive,noNo, positive^\$^, no, no, positiveDisease characteristics Faster or more progression  Lower global assessment (self-reported) at baselineModerate evidence for faster or more progression1 low risk of bias cohort \[[@CR37]\]2 cohorts \[[@CR39], [@CR50]\]PositivePositive, positive  Previous use of NSAIDsLimited evidence for more progression1 low risk of bias cohort \[[@CR37]\]Positive No association  Longer duration of symptoms at baselineModerate evidence for no association1 low risk of bias cohort \[[@CR37]\]1 cohort \[[@CR19]\]NoNo  Having another disease (comorbidity)Moderate evidence for no association1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR39]\]NoNo  Morning stiffnessModerate evidence for no association1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR51]\]NoNo  Use of pain medication at baselineModerate evidence for no association1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR19]\]NoNo  Presence of Heberden's or Bouchard's nodesModerate evidence for no association1 low risk of bias cohort \[[@CR16]\]2 cohorts \[[@CR50], [@CR51]\]NoNo, no  Previous intra-articular injection in the hipLimited evidence for no association1 low risk of bias cohort \[[@CR37]\]No Conflicting evidence  More limitations in physical function at baselineConflicting evidence3 low risk of bias cohorts \[[@CR16], [@CR34], [@CR37]\]2 cohorts \[[@CR19], [@CR39]\]Positive, positive, noNo, no  More pain at baselineConflicting evidence3 low risk of bias cohorts \[[@CR16], [@CR34], [@CR37]\]4 cohorts \[[@CR19], [@CR39], [@CR50], [@CR51]\]Conflicted^\$\$^, positive, positivePositive, no, positive, no  Painful hip flexion (active or passive)Conflicting evidence1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR51]\]PositiveNo  Painful hip internal rotation (active or passive)Conflicting evidence1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR51]\]PositiveNo  Night pain at baselineConflicting evidence2 cohorts \[[@CR50], [@CR51]\]Positive, no  Limited range of motion of flexion of the hipConflicting evidence1 low risk of bias cohort \[[@CR16]\]2 cohorts \[[@CR19], [@CR51]\]PositivePositive, no  Limited range of motion of internal hip rotationConflicting evidence1 low risk of bias cohort \[[@CR16]\]2 cohorts \[[@CR19], [@CR51]\]PositivePositive, no  Limited range of motion of external hip rotationConflicting evidence2 cohorts \[[@CR19], [@CR51]\]Positive, noChemical or imaging markers Faster or more progression  Higher K-L grade at baselineStrong evidence for more or faster progression2 low risk of bias cohorts \[[@CR34], [@CR37]\]1 cohorts \[[@CR51]\]Positive, positivePositive  Superior or superolateral migration of the femoral headStrong evidence for more or faster progression2 low risk of bias cohorts \[[@CR34], [@CR47]\]1 cohort \[[@CR38]\]Positive, positivePositive  Subchondral sclerosisStrong evidence for more progression2 low risk of bias cohorts \[[@CR16], [@CR47]\]Positive, positive  Statistical shape modelingModerate evidence that certain modes of SSM can predict progression3 cohorts \[[@CR11], [@CR12], [@CR12]\]Positive, positive, positive  Joint space narrowing at baselineModerate evidence for more or faster progression1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR67]\]PositivePositive No association  Cam-type deformity (alpha angle \> 60°)Limited evidence for no association1 low risk of bias cohort \[[@CR16]\]No Conflicting evidence  Erythrocyte sedimentation rateConflicting evidence1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR51]\]PositiveNo  Atrophic bone response (no osteophytes present)Conflicting evidence1 low risk of bias cohort \[[@CR16]\]2 cohorts \[[@CR50], [@CR51]\]PositivePositive, no  Decrease in joint space width at baselineConflicting evidence1 low risk of bias cohort \[[@CR34]\]1 cohort \[[@CR51]\]PositiveNo  Wiberg's center edge angle (CEA)Conflicting evidence1 low risk of bias cohort \[[@CR16]\]1 cohort \[[@CR20]\]NegativeNo^\$^Exception: age ≥ 82 years showed a negative association with progression, compared to age ≤ 62 years^\$\$^Pain at baseline measured with NRS past week showed a statistically significant positive association with THR; pain at baseline measured with WOMAC pain showed no statistically significant association with THR

Strong evidence was found for no association between radiological progression and the following markers: C-terminal telopeptide of collagen type I (CTX-I), cartilage oligomeric matrix protein (COMP), N-terminal telopeptide of collagen type I (NTX-I), and N-terminal propeptide of procollagen type I and type III (PINP, PIIINP) (Table [4](#Tab4){ref-type="table"}). Table 4Factors predicting radiological progressionPrognostic factorStudiesAssociationsBest-evidence synthesisPatient variables No association  Family history of OAModerate evidence for no association3 cohorts \[[@CR25], [@CR60], [@CR65]\]No, no, no  Body mass indexModerate evidence for no association4 cohorts \[[@CR25], [@CR50], [@CR61], [@CR65]\]No, no, no, no Conflicting evidence  Higher age at baseline or at first symptomsConflicting evidence1 low risk of bias cohort \[[@CR32]\]4 cohorts \[[@CR35], [@CR50], [@CR60], [@CR65]\]PositiveNo, positive, positive, no  FemaleConflicting evidence1 low risk of bias cohort \[[@CR32]\]6 cohorts \[[@CR25], [@CR27], [@CR35], [@CR50], [@CR60], [@CR65]\]PositiveNo, no, no, no, positive, noDisease characteristics Faster or more progression  More limitations in physical function at baselineModerate evidence for more progression1 low risk of bias cohort \[[@CR32]\]1 cohort \[[@CR60]\]PositivePositive  Hip pain present at baseline or on most days for a least 1 month in the past yearModerate evidence for more progression1 low risk of bias cohort \[[@CR47]\]1 cohort \[[@CR60]\]PositivePositive No association  Forestier's diseaseModerate evidence for no association3 cohorts \[[@CR25], [@CR50], [@CR65]\]No, no, no  Diabetes mellitusLimited evidence for no association2 cohorts \[[@CR25], [@CR60]\]No, no  Bilateral hip OALimited evidence for no association2 cohorts \[[@CR25], [@CR65]\]No, no  Generalized OALimited evidence for no association2 cohorts \[[@CR25], [@CR65]\]No, noChemical or imaging markers Faster or more progression  Subchondral sclerosisModerate evidence for more progression1 low risk of bias cohort \[[@CR47]\]1 cohort \[[@CR33]\]PositivePositive  Neck width of the femoral headLimited evidence for more progression1 low risk of bias cohort \[[@CR21]\]Positive  Osteocalcin (OC)Limited evidence for less progression1 low risk of bias cohort \[[@CR63]\]Negative No association  C-terminal telopeptide of collagen type I (CTX-I)Strong evidence for no association2 low risk of bias cohorts \[[@CR53], [@CR63]\]No, no  Cartilage oligomeric matrix protein (COMP)Strong evidence for no association3 low risk of bias cohorts \[[@CR44], [@CR53], [@CR63]\]1 cohort \[[@CR26]\]No, no, noPositive  N-terminal telopeptide of collagen type I (NTX-I)Strong evidence for no association2 low risk of bias cohorts \[[@CR44], [@CR63]\]No, no  N-terminal propeptide of procollagen type I (PINP)Strong evidence for no association2 low risk of bias cohorts \[[@CR53], [@CR63]\]No, no  N-terminal propeptide of procollagen type III (PIIINP)Strong evidence for no association2 low risk of bias cohorts \[[@CR53], [@CR63]\]No, no  High-sensitive C-reactive protein (hs-CRP)Moderate evidence for no association1 low risk of bias cohort \[[@CR53]\]1 cohort \[[@CR45]\]NoNo  Angle of the femoral headModerate evidence for no association1 low risk of bias cohort \[[@CR21]\]2 cohorts \[[@CR20], [@CR65]\]NoNo, no  Acetabular osteophytes onlyModerate evidence for no association1 low risk of bias cohort \[[@CR47]\]1 cohort \[[@CR33]\]NoNo  N-terminal propeptide of procollagen type IIA (PIIANP)Limited evidence for no association1 low risk of bias cohort \[[@CR63]\]No  Chondroitin sulphate 846 (CS846)Limited evidence for no association1 low risk of bias cohort \[[@CR63]\]No  Cartilage glycoprotein 40 (YKL-40)Limited evidence for no association1 low risk of bias cohort \[[@CR53]\]No  Matrix metalloproteinases (MMP-1)Limited evidence for no association1 low risk of bias cohort \[[@CR53]\]No  Matrix metalloproteinases (MMP-3)Limited evidence for no association1 low risk of bias cohort \[[@CR53]\]No  Neck length of the femoral headLimited evidence for no association1 low risk of bias cohort \[[@CR21]\]No Conflicting evidence  Bone mineral contentConflicting evidence1 low risk of bias cohort \[[@CR21]\]Conflicted^\$^  Area/size of the hip jointConflicting evidence1 low risk of bias cohort \[[@CR21]\]Conflicted^\$\$^  C-terminal telopeptide of collagen type II (CTX-II)Conflicting evidence2 low risk of bias cohorts \[[@CR53], [@CR63]\]1 cohort \[[@CR59]\]Positive, noPositive  Hyaluronic acid (HA)Conflicting evidence2 low risk of bias cohorts \[[@CR53], [@CR63]\]1 cohort \[[@CR23]\]Positive, noNo  Atrophic bone response (no osteophytes present)Conflicting evidence1 low risk of bias cohort \[[@CR47]\]3 cohorts \[[@CR25], [@CR50], [@CR65]\]NoPositive, positive, no  Subchondral cystsConflicting evidence1 low risk of bias cohort \[[@CR47]\]1 cohort \[[@CR33]\]PositiveNo  Decrease in joint space width at baselineConflicting evidence1 low risk of bias cohort \[[@CR32]\]2 cohorts \[[@CR25], [@CR60]\]PositiveNo, positive  Superior or (supero) lateral migration of the femoral headConflicting evidence2 low risk of bias cohorts \[[@CR32], [@CR47]\]2 cohorts \[[@CR25], [@CR50]\]Positive, noNo, positive  Higher K-L grade at baselineConflicting evidence4 cohorts \[[@CR33], [@CR50], [@CR60], [@CR65]\]No, positive, positive, no  Acetabular index (Horizontal toit externe angle)Conflicting evidence2 cohorts \[[@CR20], [@CR65]\]Conflicted^\$\$\$^, no  Wiberg's center edge angle (CEA)Conflicting evidence2 cohorts \[[@CR20], [@CR65]\]No, negative^\$^BMC of superior (*p* = 0.009) and medial (*p* = 0.019) quart femoral head, arc regions 2--4 (*p* = 0.02, 0.001, 0.003, respectively), and the acetabular arc was higher in patients with progression than without progression. BMC of the femoral neck (*p* = 0.17), intertrochanteric area (*p* = 0.9), trochanteric area (*p* = 0.6), and inferior (*p* = 0.08) and lateral (*p* = 0.06) quart femoral head and arc region 1 (*p* = 0.19) of acetabular arc was not significantly different between patients with or without progression^\$\$^The area/size of superior (*p* = 0.002), medial (p = 0.002), inferior (*p* = 0.003), and lateral (*p* = 0.003) femoral head and of arc regions 2--4 (*p* = 0.007, 0.001 and 0.005 respectively) of acetabular arc was higher in patients with progression than without progression. The area/size of the femoral neck (*p* = 0.6), intertrochanteric area (*p* = 0.16), trochanteric area (*p* = 0.4), and arc region 1 (*p* = 0.2) of the acetabular arc was not significantly different between patients with progression and without progression.^\$\$\$^A statistically significant association was found between the acetabular index and progression defined as ≥ 1 increase in joint space narrowing; however, no statistically significant association was found between the acetabular index and progression defined as ≥ 1 increase in K-L grade

Strong evidence showed comorbidity to be predictive of clinical progression. On the other hand, gender, social support, use of pain medication at baseline, quality of life at baseline, and limited range of motion of internal hip rotation or external hip rotation were not predictive of clinical progression (Table [5](#Tab5){ref-type="table"}). Table 5Factors predicting clinical progressionPrognostic factorStudiesAssociationsBest-evidence synthesisPatient variables No association  FemaleStrong evidence for no association2 low risk of bias cohorts \[[@CR41], [@CR57]\]5 cohorts \[[@CR13], [@CR27], [@CR42], [@CR56], [@CR66]\]No, noPositive, no, no, no, no  Social supportStrong evidence for no association2 low risk of bias cohorts \[[@CR41], [@CR57]\]No, no  Higher age at baselineModerate evidence for no association1 low risk of bias cohort \[[@CR41], [@CR57]\]3 cohorts \[[@CR42], [@CR56], [@CR66]\]No, positiveNo, no, no  Paid employmentModerate evidence for no association1 low risk of bias cohort \[[@CR41]\]2 cohorts \[[@CR42], [@CR56]\]NoNo, no  Living aloneModerate evidence for no association1 low risk of bias cohort \[[@CR41]\]1 cohort \[[@CR30]\]NoNo  Alcohol consumptionLimited evidence for no association1 low risk of bias cohort \[[@CR41]\]No Conflicting evidence  Physical activity during leisureConflicting evidence1 low risk of bias cohort \[[@CR41]\]Conflicted^\$^  Body mass indexConflicting evidence2 low risk of bias cohorts \[[@CR41], [@CR57]\]3 cohorts \[[@CR42], [@CR56], [@CR66]\]Positive, noNo, no, positive  Lower education levelConflicting evidence2 low risk of bias cohorts \[[@CR41], [@CR57]\]2 cohorts \[[@CR42], [@CR66]\]No, negativePositive, noDisease characteristics Faster or more progression  Having another disease (comorbidity)Strong evidence for more progression2 low risk of bias cohorts \[[@CR41], [@CR57]\]1 cohort \[[@CR42]\]Positive^\$\$^, positivePositive  Concurrent morning stiffness of the knee (\< 30 min)Limited evidence for more progression1 low risk of bias cohort \[[@CR41]\]Positive No association  Use of (pain) medication at baselineStrong evidence for no association2 low risk of bias cohorts \[[@CR29], [@CR41]\]No, no  Quality of life at baselineStrong evidence for no association2 low risk of bias cohort \[[@CR30], [@CR41]\]No^\$\$\$^, no  Limited range of motion of internal hip rotationStrong evidence for no association2 low risk of bias cohorts \[[@CR41], [@CR57]\]1 cohort \[[@CR66]\]No, noNo  Limited range of motion of external hip rotationStrong evidence for no association2 low risk of bias cohorts \[[@CR15], [@CR57]\]No, no  Concurrent knee painModerate evidence for no association1 low risk of bias cohort \[[@CR41]\]1 cohort \[[@CR66]\]NoNo  DepressionModerate evidence for no association1 low risk of bias cohort \[[@CR41]\]1 cohort \[[@CR56]\]NoNo  Way of copingModerate evidence for no association1 low risk of bias cohort \[[@CR41]\]1 cohort \[[@CR30]\]NoNo  Respiratory comorbidityModerate evidence for no association1 low risk of bias cohort \[[@CR29]\]1 cohort \[[@CR56]\]NoNo  Patient-rated healthLimited evidence for no association1 low risk of bias cohort \[[@CR41]\]No  Cardiac comorbidity (cumulative illness rating scale 1, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Vascular comorbidity (cumulative illness rating scale 2, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Eye, ear, nose, throat, and larynx diseases (cumulative illness rating scale 4, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Upper gastrointestinal comorbidity (cumulative illness rating scale 5, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Lower gastrointestinal comorbidity (cumulative illness rating scale 6, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Hepatic comorbidity (cumulative illness rating scale 7, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Renal comorbidity (cumulative illness rating scale 8, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Other genitourinary comorbidities (cumulative illness rating scale 9, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Neurological comorbidity (cumulative illness rating scale 11, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Psychiatric comorbidity (cumulative illness rating scale 12, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Comorbidity of endocrine and metabolic diseases (cumulative illness rating scale 13, severity score ≥ 2)Limited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Cognitive functioningLimited evidence for no association1 low risk of bias cohort \[[@CR57]\]No  Muscle strength hip abductionLimited evidence for no association1 low risk of bias cohort \[[@CR57]\]No  Pain during sitting or lyingLimited evidence for no association1 low risk of bias cohort \[[@CR41]\]No  Joint stiffness (WOMAC)Limited evidence for no association1 low risk of bias cohort \[[@CR15]\]No  Use of additional supplements or vitaminsLimited evidence for no association1 low risk of bias cohort \[[@CR15]\]No  Concurrent pain during flexion of ipsilateral kneeLimited evidence for no association1 low risk of bias cohort \[[@CR15]\]No  Knee flexionLimited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Knee extensionLimited evidence for no association1 low risk of bias cohort \[[@CR29]\]No  Strength of isometric knee extensionLimited evidence for no association1 low risk of bias cohort \[[@CR29]\]No Conflicting evidence  Bilateral hip OAConflicting evidence1 low risk of bias cohort \[[@CR41]\]1 cohort \[[@CR66]\]Positive, if equal symptomsNo  Pain at baseline (self-reported or during physical examination)Conflicting evidence3 low risk of bias cohorts \[[@CR29], [@CR41], [@CR47]\]No, no, positive  Longer duration of symptoms at baselineConflicting evidence1 low risk of bias cohort \[[@CR57]\]2 cohorts \[[@CR42], [@CR66]\]NoNo, positive  Morning stiffnessConflicting evidence1 low risk of bias cohort \[[@CR41]\]1 cohort \[[@CR66]\]NoPositive  Limited range of motion of flexion of the hipConflicting evidence2 low risk of bias cohorts \[[@CR41], [@CR57]\]1 cohort \[[@CR66]\]Positive, noNoChemical or imaging markers Conflicting evidence  Higher K-L grade at baselineConflicting evidence1 low risk of bias cohort \[[@CR12]\]2 cohorts \[[@CR42], [@CR66]\]NoNo, positive^\$^Patients who were 3--5 days/week physically active in their leisure time showed less progression than patients who were 0--2 days/week physically active in their leisure time. No difference was found between patients spending 6--7 days/week on physical activity and patients spending 0--2 days/week on physical activity^\$\$^≥ 3 more diseases compared to no comorbidities^\$\$\$^Subscale of SF-36 vitality showed a positive association with WOMAC function score

For other factors, only moderate, limited, or conflicting evidence was found for predicting or not predicting progression (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, and [5](#Tab5){ref-type="table"}).

Discussion {#Sec15}
==========

In this study, we systematically reviewed all 154 factors predictive of progression of hip OA, reported in 57 studies. Compared to earlier reviews, there was a considerable amount of additional evidence available for the factors previously reported in reviews, as well as evidence for factors not earlier described.

In this review, some results had changed compared to the review of Lievense et al. in 2002 \[[@CR2]\]. Firstly, because of the new evidence emerging from the later studies, especially studies with a clinical outcome of progression. Secondly, because we used a different method to assess the risk of bias, some studies were no longer considered to have a low risk of bias. The QUIPS tool seems to apply stricter criteria than the method used by Lievense et al. in 2002. Thirdly, we divided the outcomes into three different groups of progression. Thus, due to these methodological differences (together with additional studies), we were unable to confirm an atrophic bone response as a predictor for radiological progression or progression to THR. On the other, we were able to confirm their conclusion on BMI as not predictive of progression and faster progression in patients with a superolateral migration of the femoral head.

Most of the prognostic factors reported by Wright et al. in 2009 \[[@CR3]\] were confirmed in this present review in one or more of the outcome groups. The differences found in age, femoral and acetabular osteophytes, and hip pain at baseline were (as with Lievense et al.) a combination of new evidence, differences in the risk of bias assessment, and the division into defined groups of progression. The study from de Rooij et al. in 2016 \[[@CR4]\] reviewed the evidence for predictors of the course of pain and function and found comorbidity and vitality (SF-36) to be predictive of function, as we found for clinical progression. However, although they also used the QUIPS tool to assess the risk of bias, they used a different cutoff point to classify a study as having a low risk of bias. Therefore, some earlier findings of strong evidence for no association with the course of pain or function were confirmed as only moderate evidence for no association with clinical progression in our review. Other differences between this review and the present one are mainly attributable to the differences in the selection criteria. In Table [6](#Tab6){ref-type="table"}, we summarized all factors with strong evidence to be predictive of progression found in one of these four reviews and the overlap and differences in evidence for these factors. Table 6Overview of factors with strong evidence to be predictive of progression, overlap and differences between this review and the review of de Rooij et al., Wright et al., and Lievense et al.Prognostic factorTeirlinck et al. factor predictive ofDe Rooij et al. factor predictive ofWright et al. factor predictive ofLievense et al. factor predictive ofK-L grade at baseline**THR**Strong evidence for no association for clinical progression**Radiological progression or THR**\*Not mentionedSubchondral sclerosis at baseline**THR**Not mentioned**Radiological progression and/or THR**Not mentionedSuperior or (supero) lateral femoral head migration**THR**Not mentioned**Radiological progression and/or THRRadiological progression and/or THR**Comorbidity**Clinical progressionClinical progression (strong evidence for a course of function, weak evidence for a course of pain)**Not mentionedNot mentionedLow vitalityQuality of life in general: strong evidence of no association, specific for SF 36 vitality: strong evidence for clinical progression**Course of function**Not mentionedNot mentionedAgeConflicted evidence for THR and radiological progression, moderate evidence for no association with clinical progressionStrong evidence for no association with pain and conflicted evidence for function**Radiological progression and/or THR**Conflicted evidenceFemoral osteophytesConflicted evidenceNot mentioned**Radiological progression and/or THR**Not mentionedHip pain at baselineConflicted evidenceConflicted evidence**Radiological progression and THR**Not mentionedJSW at baselineConflicted evidenceNot mentioned**Radiological progression and/or THR**Limited evidence for THRLequesne index score ≥ 10 at baselineConflicted evidence for THR, moderate evidence for radiological progression\*\*Conflicted evidence\*\***Radiological progression and/or THR**Not mentionedAtrophic bone responseConflicted evidenceNot mentionedConflicted evidence**Radiological progression**\*K-L grade 3 at baseline\*\*Function at baseline in generalbold text represents strong evidence to be predictive of progression

Strengths of this present review are the sensitive literature search and our systematic approach to the selection, risk of bias assessment, and the best-evidence synthesis. Therefore, we have presented an extensive overview of reported prognostic factors and existing evidence for their associations. In performing the evidence synthesis divided into outcome (radiological, clinical, or THR), we decreased the heterogeneity and we believe the results to be more accurate for daily practice. Unfortunately, heterogeneity was still too high to perform a meta-analysis. Therefore, we were bound to a best-evidence synthesis and unable to calculate the strengths of the associations. This limits the translation to the daily clinical practice. Another disadvantage of this synthesis compared to a meta-analysis is that smaller studies contribute to the result with the same weight as larger studies, even though the smaller studies may have low power to show a statistically significant association.

In the selection of studies, several restrictions were imposed. First, languages were restricted to ensure that at least two researchers had a reasonable understanding of the languages included so all articles were reliably assessed. However, this implies that we may have missed studies from countries in which publication in English is less common. Secondly, negative results (i.e., no association was found) are less likely to be published and are therefore not well represented in this review.

We used the QUIPS tool to assess the risk of bias. Nine other studies using this tool reported an inter-rater agreement ranging from 70 to 89.5% (median 83.5%) and a kappa statistic ranging from 0.56 to 0.82 (median 0.75) \[[@CR7]\]. Compared to these data, our inter-rater agreement was low and considered to be moderate. Disagreement was mainly due to the differences in interpretation of items of the QUIPS tool; however, only for very few items, a third reviewer was needed to make a final decision.

Hip dysplasia and femoral acetabular impingement were initially considered to be underlying pathologies and were excluded from this analysis. However, the range of severity of these morphologies is substantial, i.e., some of these morphologies should clearly be considered as an underlying pathology, whereas others are more subtle and sometimes undiagnosed. These subtle morphologies might be considered to be possible prognostic factors, rather than underlying pathologies. Therefore, all citations were screened using the terms "hip dysplasia" and "femoral acetabular impingement" in the title or abstract. However, we found only one small study \[[@CR35]\] which investigated the radiographic findings of femoral acetabular impingement as a prognostic factor (results of this study are included in Additional file [4](#MOESM4){ref-type="media"}). In the studies already included, three studies did not specifically include patients with hip dysplasia or femoral acetabular impingement but did investigate the associated angles (Wiberg's center edge angle and alpha angle, respectively). Since the evidence for these associations with the progression of hip OA was weak, future studies and reviews should investigate these morphologies as possible prognostic factors.

Conclusion {#Sec16}
==========

We conclude that there is consistent evidence that four factors (comorbidity, K-L grade, superior or (supero) lateral femoral head migration, and subchondral sclerosis) were predictive of progression of hip OA, whereas 12 factors were not predictive. The evidence for other factors was weak or conflicting. Health professionals caring for patients with hip OA will benefit from the insight in prognostic factors, e.g., patients more likely to progress rapidly may need an intensified symptomatic treatment or early referral to an orthopedic surgeon. For this, we still need more high-quality research focusing on the prognostic factors in hip OA.

Additional files
================

 {#Sec17}

Additional file 1:Syntax of literature search. (DOCX 15 kb) Additional file 2:Criteria items of QUIPS tool and possible adjustments. (DOCX 42 kb) Additional file 3:Characteristics of the selected studies: extensive overview. (DOCX 172 kb) Additional file 4:Prognostic factors described by one study or multiple studies from the same cohort. (DOCX 126 kb) Additional file 5:Factors predicting total hip replacement, clinical or radiological progression combined. (DOCX 82 kb)

BMI

:   Body mass index

COMP

:   Cartilage oligomeric matrix protein

CS846

:   Chondroitin sulphate 846

CTX-I

:   C-terminal telopeptide of collagen type I

CTX-III

:   C-terminal telopeptide of collagen type II

ESR

:   Erythrocyte sedimentation rate

GRADE

:   Grading of Recommendations Assessment, Development and Evaluation

HA

:   Hyaluronic acid

hs-CRP

:   High-sensitive C-reactive protein

JSN

:   Joint space narrowing

JSW

:   Joint space width

K-L grade

:   Kellgren and Lawrence grade

LCGA

:   Latent class growth analysis

MJS

:   Minimum joint space

MMP-1

:   Matrix metalloproteinases-1

MMP-3

:   Matrix metalloproteinases-3

MRI

:   Magnetic resonance imaging

NRS

:   Numeric rating scale

NTX-I

:   N-terminal telopeptide of collagen type I

OA

:   Osteoarthritis

OC

:   Osteocalcin

PIIANP

:   N-terminal propeptide of procollagen type IIA

PIIINP

:   N-terminal propeptide of procollagen type III

PINP

:   N-terminal propeptide of procollagen type I

QUIPS

:   Quality in prognosis studies

THR

:   Total hip replacement

VAS

:   Visual analog scale

WOMAC

:   Western Ontario and McMaster Universities Osteoarthritis Index

YKL-40

:   Cartilage glycoprotein 40

YMN

:   Yearly mean narrowing
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